The use of alpha-2-macroglobulin as a novel treatment for patients with chronic pelvic pain syndrome.

Abstract

Chronic pelvic pain syndrome (CPPS), defined as continuous or recurrent pain in the pelvic region lasting at least six months, which cannot be wholly attributed to a single organ or distinct pathology [1], has a multifactorial etiology involving the gynecologic, urologic, gastrointestinal, musculoskeletal and/or neurologic systems. Aberrant pain signal processing and local tissue responses are contributive factors [2]. Current recommendations for management are multimodal and include physical therapy, pharmacotherapy, cognitive behavioral therapy, and interventional procedures [1].